# EIU-104101 (NCT07217171)

> A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas

No report yet. It can be ordered.

- Drugs tested: EVOLVE104
- Indication: advanced urothelial and squamous cell carcinomas

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT07217171
- Phase: PHASE1
- Status: RECRUITING
- Sponsor: EvolveImmune United, Inc
- Conditions: Bladder Cancer; Squamous Cell Carcinoma of the Lung; Esophageal Squamous Cell Carcinoma; Tongue Squamous Cell Carcinoma; Cutaneous Squamous Cell Cancer; Penile Squamous Cell Carcinoma; Anal Squamous Cell Carcinoma; Vulvar Squamous Cell Carcinoma; Cervical Squamous Cell Carcinoma; Vaginal Squamous Cell Carcinoma; Urethral Squamous Cell Carcinoma
- Interventions: EVOLVE104; EVOLVE104
- Enrollment: 160
- Primary outcome: Incidence and Severity of Treatment Emergent Adverse Events (TEAEs)
- Primary outcome: Number of patients with Dose Limiting Toxicities (DLTs)
- Primary outcome: To determine the maximum tolerated dose (MTD) and/or recommended dose(s) for expansion (RDEs) for EVOLVE104
- Primary outcome: To determine the recommended phase 2 dose (RP2D) of EVOLVE104

## Indexed commentary on EIU-104101 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=eiu-104101-nct07217171
